Clinical Trial Update: Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases [Phase 2]

View source ↗

Summary

This Phase 2 trial of lenvatinib plus pembrolizumab in immune-refractory metastatic renal cell carcinoma with brain metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma, Brain Metastasis | Phase 2 | Status: WITHDRAWN